You searched for Tourette syndrome

News and Trends 3 Nov 2022

Trial and new drug for Tourette Syndrome after $250M after funding round completed

A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […]

November 3, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 12 May 2023

Five latest advancements in Tourette’s syndrome research

Named after French neurologist Georges Gilles de la Tourette, who first described the disorder in 1885, Tourette’s syndrome is estimated to affect one in 10 to 1000 people worldwide. A neurological condition, the disorder causes involuntary movements and sounds, commonly known as tics. Although its exact cause isn’t known, research points to a link between […]

May 12, 2023 - 7 minutesmins - By Roohi Mariam Peter

tourette syndrome treatment noema pharma

News and Trends 7 Dec 2020

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

In spite of recent failures of clinical trials from others in the field, Swiss company Noema Pharma is gearing up to develop better treatments for the neurological condition Tourette’s syndrome. Noema Pharma will use a recent €49M Series A round to bankroll the phase I development of a candidate for Tourette’s syndrome along with the […]

December 7, 2020 - 3 minutesmins - By Jonathan Smith

Best in Biotech 2 Apr 2024

Chicago biotech: Seven players advancing the industry

Chicago is a prominent city for biotech with a blend of established entities and promising startups. Delve into Chicago’s biotech ecosystem.

April 2, 2024 - 8 minutesmins - By Jules Adam

News and Trends 8 Mar 2023

Noema Pharma raises $112 million in Series B financing

Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor […]

March 8, 2023 - 2 minutesmins - By Jim Cornall

In Depth 5 Dec 2022

The biggest private biotech investments in November 2022

The companies Emalex Biosciences, Osler Diagnostics and TauRx Pharmaceuticals bagged the biggest biotech investments in November 2022. Around the world, oncology and cell therapy players attracted the biggest funding rounds. We’re approaching the December holidays and, while lower than in 2021, biotech stocks overall have stayed relatively flat in the last few months. In the […]

December 5, 2022 - 4 minutesmins - By Jonathan Smith

Health Awareness Days

Here at Labiotech.eu we often coordinate coverage based on special events. Sometimes, that’s conferences and shows, but we also cover health awareness days, weeks, or months, as well. There are lots of awareness events associated with these special awareness anniversaries, raising much-needed funds for charities tackling the diseases and conditions. We didn’t include such events, […]

November 24, 2022 - 1 minutemin - By Aurore Michelin

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us